NEW YORK (GenomeWeb) – Molecular diagnostics firm Rosetta Genomics yesterday reported a 23 percent rise in second quarter revenues on strong growth in its urologic cancer testing services business.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.